EA201170689A1 - Противомикробные композиции - Google Patents

Противомикробные композиции

Info

Publication number
EA201170689A1
EA201170689A1 EA201170689A EA201170689A EA201170689A1 EA 201170689 A1 EA201170689 A1 EA 201170689A1 EA 201170689 A EA201170689 A EA 201170689A EA 201170689 A EA201170689 A EA 201170689A EA 201170689 A1 EA201170689 A1 EA 201170689A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
microbial compositions
tolerability
prophylaxis
risk
Prior art date
Application number
EA201170689A
Other languages
English (en)
Other versions
EA025637B1 (ru
Inventor
Данпин Ли
Эрик С. Бьюрак
Дэвид С. Дресбэк
Дэниелль Берер Лорд
Original Assignee
Риб-Экс Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Риб-Экс Фармасьютикалз, Инк. filed Critical Риб-Экс Фармасьютикалз, Инк.
Publication of EA201170689A1 publication Critical patent/EA201170689A1/ru
Publication of EA025637B1 publication Critical patent/EA025637B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)

Abstract

Изобретение относится к противомикробным композициям и, более конкретно, к композициям производных хинолонкарбоновой кислоты. Указанные композиции обладают улучшенной растворимостью, стабильностью и переносимостью. Указанные композиции подходят для внутривенного введения для лечения, профилактики или снижения риска возникновения инфекционного заболевания.
EA201170689A 2008-11-15 2009-11-12 Противомикробные композиции EA025637B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19925308P 2008-11-15 2008-11-15
PCT/US2009/064220 WO2010056872A2 (en) 2008-11-15 2009-11-12 Antimicrobial compositions

Publications (2)

Publication Number Publication Date
EA201170689A1 true EA201170689A1 (ru) 2013-10-30
EA025637B1 EA025637B1 (ru) 2017-01-30

Family

ID=42170697

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170689A EA025637B1 (ru) 2008-11-15 2009-11-12 Противомикробные композиции

Country Status (24)

Country Link
US (4) US20120065186A1 (ru)
EP (1) EP2373166A4 (ru)
JP (3) JP6063123B2 (ru)
KR (1) KR101767689B1 (ru)
CN (3) CN102215690B (ru)
AU (1) AU2009314072C1 (ru)
BR (2) BR122020021551B1 (ru)
CA (1) CA2743419C (ru)
CO (1) CO6382082A2 (ru)
CR (1) CR20110320A (ru)
EA (1) EA025637B1 (ru)
EC (1) ECSP11011119A (ru)
HK (1) HK1213821A1 (ru)
IL (1) IL212781A (ru)
MA (1) MA32931B1 (ru)
MX (1) MX2011005117A (ru)
MY (3) MY194407A (ru)
NI (1) NI201100097A (ru)
NZ (1) NZ593345A (ru)
PE (2) PE20160116A1 (ru)
SV (1) SV2011003907A (ru)
UA (1) UA102709C2 (ru)
WO (1) WO2010056872A2 (ru)
ZA (1) ZA201104108B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6063123B2 (ja) * 2008-11-15 2017-01-18 メリンタ セラピューティクス、インク 抗菌性組成物
EP3446692A1 (en) * 2011-11-29 2019-02-27 Jurox Pty. Ltd. Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
JP6395200B2 (ja) * 2012-10-22 2018-09-26 ジェクス株式会社 ケイ素含有化合物水溶液及び該水溶液を含む抗菌・抗ウィルス剤
CA2903755A1 (en) * 2013-03-08 2014-09-12 Melinta Therapeutics, Inc. Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate
TWI641372B (zh) * 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
CN106458999B (zh) 2014-03-26 2019-12-03 阿斯特克斯治疗有限公司 组合
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2017159585A1 (ja) 2016-03-14 2017-09-21 参天製薬株式会社 メグルミン又はその塩からなる防腐剤
CN107789324B (zh) * 2016-08-31 2021-05-25 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺及其制备方法
CN107789323B (zh) * 2016-08-31 2021-05-07 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
MX2021007061A (es) * 2017-02-15 2022-10-07 Taiho Pharmaceutical Co Ltd Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998A (en) 1849-01-02 Improvement in combined plows
US436A (en) 1837-10-23 Brick mold used in brick-pressing machines
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
PT911327E (pt) 1995-09-22 2002-05-31 Wakunaga Pharma Co Ltd Novos derivados do acido piridonocarboxilico ou seus sais e agente antibacteriano compreendendo os mesmos como o ingrediente activo
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
EP2305666B1 (en) 2004-07-30 2014-06-25 AbbVie Inc. Preparation of pyridonecarboxylic acid antibacterials
HUE056718T2 (hu) 2004-10-08 2022-03-28 Abbvie Inc Hatóanyag (delafloxacin) meglumin sója és ennek kristályos formái
MX2007012642A (es) * 2005-04-11 2008-01-11 Abbott Lab Composiciones farmaceuticas que tienen perfiles mejorados de disolucion para farmacos poco solubles.
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070238720A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
JPWO2006134877A1 (ja) * 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
JP6063123B2 (ja) * 2008-11-15 2017-01-18 メリンタ セラピューティクス、インク 抗菌性組成物

Also Published As

Publication number Publication date
UA102709C2 (ru) 2013-08-12
IL212781A (en) 2016-12-29
CN102215690A (zh) 2011-10-12
US20200022971A1 (en) 2020-01-23
WO2010056872A3 (en) 2010-07-29
BRPI0921705B8 (pt) 2021-05-25
MY161597A (en) 2017-04-28
JP6063123B2 (ja) 2017-01-18
CN103705942B (zh) 2016-08-24
MA32931B1 (fr) 2012-01-02
WO2010056872A2 (en) 2010-05-20
IL212781A0 (en) 2011-07-31
KR101767689B1 (ko) 2017-08-11
EA025637B1 (ru) 2017-01-30
JP6407221B2 (ja) 2018-10-17
MY188453A (en) 2021-12-09
EP2373166A2 (en) 2011-10-12
CO6382082A2 (es) 2012-02-15
CR20110320A (es) 2011-10-18
JP2017031164A (ja) 2017-02-09
PE20160116A1 (es) 2016-03-09
NI201100097A (es) 2011-09-08
SV2011003907A (es) 2011-12-06
BRPI0921705B1 (pt) 2021-01-19
CN104958296B (zh) 2017-12-01
BRPI0921705A2 (pt) 2015-08-25
CN103705942A (zh) 2014-04-09
AU2009314072A1 (en) 2011-06-30
JP2015091856A (ja) 2015-05-14
CN102215690B (zh) 2015-07-01
US20220265636A1 (en) 2022-08-25
CA2743419A1 (en) 2010-05-20
CN104958296A (zh) 2015-10-07
JP2012508757A (ja) 2012-04-12
EP2373166A4 (en) 2014-11-05
HK1213821A1 (zh) 2016-07-15
MY194407A (en) 2022-11-30
AU2009314072C1 (en) 2016-11-10
US20160235736A1 (en) 2016-08-18
NZ593345A (en) 2013-04-26
US20120065186A1 (en) 2012-03-15
KR20120008020A (ko) 2012-01-25
PE20120029A1 (es) 2012-02-13
ZA201104108B (en) 2012-09-26
AU2009314072B2 (en) 2016-05-19
ECSP11011119A (es) 2011-11-30
BR122020021551B1 (pt) 2021-09-21
CA2743419C (en) 2017-02-14
MX2011005117A (es) 2011-10-21

Similar Documents

Publication Publication Date Title
EA201170689A1 (ru) Противомикробные композиции
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
IN2012DN01453A (ru)
EA201390198A1 (ru) Гетероциклическое соединение
ATE536172T1 (de) Ezetimibzusammensetzungen
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
UA105018C2 (ru) Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости
NZ596628A (en) Ketolide compounds having antimicrobial activity
WO2011006935A3 (en) Tetrazole derivatives
EA201290229A1 (ru) Производные спиролактама и их применение
BR112012013199A2 (pt) composto, composição farmacêutica, e , uso de um composto
EA201171269A1 (ru) Лечение инфекционных болезней
EA201270547A1 (ru) Фармацевтическая композиция
MX2019012608A (es) Composiciones antimicrobianas con agentes efervescentes.
EA201390764A1 (ru) Фармацевтические композиции
UA110098C2 (uk) Композиція, що містить цефтаролін фозамілу, для лікування бактеріальної інфекції
WO2011002425A3 (en) Pharmaceutical composition increasing solubility and stability
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title